Back to search results

eSight Go At-Home Usage for Visual Impairment

This study is testing an updated version of a wearable device called eSight Go. This device helps people with vision impairment by enhancing images to make daily activities easier. You might be able to join if you are 18 to 90 years old, have vision between 20/50 and 20/400 in your better eye due to an eye condition, and your vision has been stable for at least six months. The study will look at whether using eSight Go improves your visual sharpness (visual acuity) and your ability to read. The study is currently unclear on its recruitment status and plans to enroll about 50 people.

Study design
This is an interventional study, meaning participants will receive a specific device to use. It plans to enroll about 50 participants.
What's involved
You will receive training on the eSight Go device and then take it home for four weeks to use in your daily life. A research team member will call you weekly to help with troubleshooting and device use strategies.
Compensation
Not stated in the trial record.
Follow-up
Your visual acuity and reading performance will be measured again after four weeks of using the device.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07149259

Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment

Recruiting
NAAges 18–90InterventionalTreatment
Brooks Rehabilitation
~50 participants
Updated 2025-08-29 on ClinicalTrials.gov
What's tested:At Home Use

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Visual Acuity
Measured over Pre-intervention and post-intervention at 4 weeks
+1 more outcome measured

Conditions

Low Vision Aids

Explore related trials

Low Vision

NCT07149259

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brooks Rehabilitation

    Jacksonville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Katelyn Jordan, D.O. · PRINCIPAL_INVESTIGATOR · Brooks Rehabilitation

Who to contact

Hannah Grimes
[email protected]
904-597-3478
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 18 to 90.
Best-corrected visual acuity between 20/50 to 20/400 in the better eye.
Subjects who have been diagnosed with an ocular condition causing visual impairment
Have a functional binocular field of view of at least 20 degrees.
Visual status stable for at least six months.
Demonstrate visual benefit from magnification.
Agree to wear the eSight Go in a variety of situations in the home and community.
Score ≥ 20 on the Short Orientation-Memory-Concentration Test of Cognitive Impairment (OMCT).
Subject must be able to provide an informed consent
Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.

Exclusion

Participant must not be currently undergoing any medical or surgical procedures resulting in unstable vision.
Participants who have undergone cataract, refractive, or other surgical procedures related to vision in the six-month period prior to study enrollment.
Severe (\>20/400) visual impairment in the better seeing eye.
Cognitive limitations (\< 20 on OMCT).
Participants who have undergone any vision-related injections (e.g. anti-VEGF) in the two-month period prior to the study because of active bleeding in the retina. Ongoing anti-VEGF treatments are permitted if the participant is in a "Treat and Extend" or pro re nata ("PRN") disease management, and macula is dry.
Participants are unable or unwilling to adhere to the examination schedules as they are described in the study protocol. This may also include participants already enrolled, who for whatever reason, have become unable or unwilling to continue the study. This may also include participants for whom the travel time to/from the study site is unacceptable.
Participants who self-report a history of alcoholism, drug abuse, or psychosis.
Participants who exhibit clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
Participants who may have a conflict of interest with eSight Corp, which could reasonably influence their participation in the study.
Refractive error outside the range correctable by lens inserts in the device (\> +/-8.00 D sph or -4.00 cyl)

What this trial measures

  • Change in Visual AcuityPre-intervention and post-intervention at 4 weeks

    Early Treatment Diabetic Retinopathy Study Chart (ETDRS) assessing visual acuity. A lower logMAR value indicates an improved score.

  • Change in Reading PerformancePre-intervention and post-intervention at 4 weeks

    Minnesota Low Vision Reading Test assessing reading performance. A lower logMAR value indicates an improved score.